openPR Logo
Press release

EMEA Soliris Drug Market Research Report 2018- QY Research, Inc.

07-13-2018 07:25 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: QY Research, Inc. 

EMEA Soliris Drug Market Research Report 2018- QY Research, Inc.

In this report, the EMEA Soliris Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Soliris Drug for these regions, from 2013 to 2025 (forecast)

Europe: Germany, France, UK, Russia, Italy and Benelux;

Middle East: Saudi Arabia, Israel, UAE and Iran;

Africa: South Africa, Nigeria, Egypt and Algeria.

Request Sample Copy of the Report @ https://www.qyresearch.com/sample-form/form/553445/emea-europe-middle-east-and-africa-soliris-drug-market

EMEA Soliris Drug market competition by top manufacturers/players, with Soliris Drug sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

Alexion

...

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

Plasma Exchange

Plasma Infusion

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

PNH

aHUS

Other

Click to view the full report TOC, figure and tables: https://www.qyresearch.com/index/detail/553445/emea-europe-middle-east-and-africa-soliris-drug-market

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert’s resources (included energy automotive chemical medical ICT consumer goods etc.

QY Research, INC.
17890 Castleton,
Suite 218,
City of industry, CA - 91748
USA: +1 626 295 2442
Email – inquiry@qyrsearch.com
Web – www.qyresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release EMEA Soliris Drug Market Research Report 2018- QY Research, Inc. here

News-ID: 1123826 • Views:

More Releases from QY Research, Inc. 

Industrial Zeolite Molecular Sieves Market Opportunity Assessment, Market Challe …
LOS ANGELES, United States: The global Industrial Zeolite Molecular Sieves market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Industrial Zeolite Molecular Sieves market. For instance, the market dynamics section digs deep into the
Pseudo Boehmite Market COVID-19 Impact Analysis, Growth Potential, Price Trend, …
LOS ANGELES, United States: The global Pseudo Boehmite market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Pseudo Boehmite market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and
Non-shrink Cement Grout Market 2021-2027: Value of Size, Share, and Prospective …
LOS ANGELES, United States: The global Non-shrink Cement Grout market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Non-shrink Cement Grout market. For instance, the market dynamics section digs deep into the drivers, restraints,
Expansive Cement Market Size 2021, Profiles, Types and Application of Top Compan …
LOS ANGELES, United States: The global Expansive Cement market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Expansive Cement market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and

All 5 Releases


More Releases for Soliris

Global Soliris Market Outlook 2025-2034: Trends, Innovations, And Future Outlook
The Soliris Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Soliris Market Size and Projected Growth Rate? In recent times, the Soliris market has experienced significant growth. The market, which stood at $1,880.37 million in 2024, is anticipated to increase to $2,030.44 million
Future Outlook of the Soliris Intravenous Market: Soliris Intravenous Trends and …
The global Soliris Intravenous Market was valued at approximately USD 3.5 billion in 2024 and is projected to reach around USD 6.8 billion by 2033, growing at a compound annual growth rate (CAGR) of about 7.5% from 2025 to 2033. Request a sample copy of this report at: https://www.omrglobal.com/request-sample/soliris-intravenous-market Soliris Intravenous Market Overview: The Soliris Intravenous Market is experiencing steady growth driven by the increasing prevalence of rare and chronic diseases such as
Global Soliris Intravenous Market Future Prediction Report By 2032
The global Soliris intravenous market was valued at approximately USD 4.23 billion in 2023 and is projected to reach around USD 7.12 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.2% from 2024 to 2032. Global Soliris Intravenous Market Overview Soliris (eculizumab) is a monoclonal antibody developed by Alexion Pharmaceuticals to treat rare, life-threatening diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and
Soliris Drug Market: An In-Depth Analysis
The market size for Soliris (eculizumab) was estimated at approximately USD 4.2 billion in 2023 and is projected to reach around USD 9.7 billion by 2032, indicating a compound annual growth rate (CAGR) of 9.7% from 2024 to 2032. Soliris Drug Market Overview The Soliris (eculizumab) drug market plays a crucial role in the treatment of rare and life-threatening diseases, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS),
Growing Prevalence Of Rare Blood Disorders To Drive Soliris Market Expansion: Ma …
How Will the Soliris Market Grow, and What Is the Projected Market Size? The market size of Soliris has experienced significant growth in the past few years. Its expansion from $1,880.37 million in 2024 to $2,030.44 million in 2025 represents a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this growth during the historic period include regulatory approvals, increased awareness of rare diseases, a rising demand for complement inhibition,
Soliris Market Size, Growing Demand to 2033 Alexion
Soliris (eculizumab) is a groundbreaking monoclonal antibody used to treat rare, life-threatening diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). It works by inhibiting the complement system, a part of the immune response that can attack healthy cells when overactivated. Approved by the FDA in 2007, Soliris was one of the most expensive drugs globally, reflecting its role in addressing ultra-rare conditions.